Adaptive Biotechnologies Corp
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair’s Growth Stoc
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.
Congressional Trades in $ADPT
No disclosed congressional trades found in $ADPT.
Insider Trades (Form 4)
OWEN KATEY EINTERZ
OWEN KATEY EINTERZ
HERSHBERG ROBERT
ROBINS CHAD M
BOBULSKY SUSAN
BOBULSKY SUSAN
ROBINS HARLAN S
BOBULSKY SUSAN
Key People
OWEN KATEY EINTERZ
Director
HERSHBERG ROBERT
Director
ROBINS CHAD M
CEO and Chairman
ROBINS HARLAN S
Chief Scientific Officer
BENZENO SHARON
Chief Commercial Ofc Imm Med
GRIFFIN MICHELLE RENEE
Director
BOBULSKY SUSAN
Chief Commercial Officer, MRD
LO FRANCIS
Chief People Officer
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro